This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Investigational Compounds

We are dedicated to delivering first-in-class cancer cell-directed therapies, and boldly pursuing innovative strategies in immuno-oncology, as well as designing smart combinations.

Combination approaches

Explore the videos and materials below to learn more about how Boehringer Ingelheim are taking cancer on.

Video
Discover how our R&D programmes are aiming to develop exceptional medicines for cancer patients
Discover how our R&D programmes are aiming to develop exceptional medicines for cancer patients
Video
Norbert Kraut outlines our leading programme of cancer cell-directed research approaches
Norbert Kraut outlines our leading programme of cancer cell-directed research approaches
Video
Jonathon Sedgwick discusses our long-term commitment to immuno-oncology research
Jonathon Sedgwick discusses our long-term commitment to immuno-oncology research
Video
Explore our immuno-oncology research strategies to target cold tumours with Jonathon Sedgwick
Explore our immuno-oncology research strategies to target cold tumours with Jonathon Sedgwick

Did you find this information useful?

Xentuzumab (BI 836845), VEGF/ANG2 inhibitor (BI 836880), MDM2-p53 antagonist (BI 907828), BET inhibitor (BI 894999), PD-1 inhibitor (BI 754091), LAG-3 inhibitor (BI754111), SMAC mimetic (BI 891065), LRP5/6 antagonist (BI 905677), SIRPα myeloid checkpoint inhibitor (BI 765063), SOS1::KRAS inhibitor (BI 1701963), mRNA vaccine (BI 1361849) are investigational compounds and have not been approved. Their safety and efficacy have not been established.

Page last updated: October 2019